Direct medical cost related to the management of pemphigus: A pilot Tunisian study.

Q3 Medicine
Faten Hayder, Emna Bahloul, Sourour Yaich, Sana Turki, Khadija Sellami, Noureddine Litaiem, Hatem Masmoudi, Manel Turki, Hamida Turki
{"title":"Direct medical cost related to the management of pemphigus: A pilot Tunisian study.","authors":"Faten Hayder, Emna Bahloul, Sourour Yaich, Sana Turki, Khadija Sellami, Noureddine Litaiem, Hatem Masmoudi, Manel Turki, Hamida Turki","doi":"10.62438/tunismed.v102i2.4651","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pemphigus is a therapeutically challenging disease with high morbidity and economic burden. First-line prescription of rituximab remains limited in Tunisia due to its high cost. Systemic steroids remain the standard of care but are associated with a major risk of morbidities and higher treatment costs.</p><p><strong>Aim: </strong>To assess the direct medical costs of pemphigus in Tunisia.</p><p><strong>Methods: </strong>Retrospective estimation of direct medical costs during the 18 months following the diagnosis using the \"bottom-up approach\" in the Dermatology Department of Hedi Chaker Hospital, Sfax, Tunisia.</p><p><strong>Results: </strong>Total medical costs were estimated at 38745.7 €, with an average cost of 1 210 € per patient and per year: paraclinical investigations (46%), medical treatment (30%), hospitalization (21%) and outpatient visits (3%). The average cost was the highest in the age group of 15-24 years (1553 €). Treatment costs related to corticosteroid-induced morbidity were estimated at 1208 €.</p><p><strong>Conclusions: </strong>The management of pemphigus in Tunisia needs to be adapted to take into account the health economic analysis in order to reduce overall disease costs and the burden of steroid-induced morbidities.</p>","PeriodicalId":38818,"journal":{"name":"Tunisie Medicale","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358821/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tunisie Medicale","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62438/tunismed.v102i2.4651","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Pemphigus is a therapeutically challenging disease with high morbidity and economic burden. First-line prescription of rituximab remains limited in Tunisia due to its high cost. Systemic steroids remain the standard of care but are associated with a major risk of morbidities and higher treatment costs.

Aim: To assess the direct medical costs of pemphigus in Tunisia.

Methods: Retrospective estimation of direct medical costs during the 18 months following the diagnosis using the "bottom-up approach" in the Dermatology Department of Hedi Chaker Hospital, Sfax, Tunisia.

Results: Total medical costs were estimated at 38745.7 €, with an average cost of 1 210 € per patient and per year: paraclinical investigations (46%), medical treatment (30%), hospitalization (21%) and outpatient visits (3%). The average cost was the highest in the age group of 15-24 years (1553 €). Treatment costs related to corticosteroid-induced morbidity were estimated at 1208 €.

Conclusions: The management of pemphigus in Tunisia needs to be adapted to take into account the health economic analysis in order to reduce overall disease costs and the burden of steroid-induced morbidities.

与丘疹性荨麻疹治疗相关的直接医疗成本:突尼斯试点研究。
导言:丘疹性荨麻疹是一种具有治疗挑战性的疾病,发病率高,经济负担重。由于价格昂贵,利妥昔单抗在突尼斯的一线处方仍然有限。系统性类固醇仍然是治疗的标准,但与发病率和较高治疗费用相关的风险较大:方法:采用 "自下而上法",对突尼斯斯法克斯Hedi Chaker医院皮肤科确诊后18个月内的直接医疗费用进行回顾性估算:医疗总费用估计为 38745.7 欧元,每位患者每年的平均费用为 1 210 欧元:临床旁检查(46%)、医疗(30%)、住院(21%)和门诊(3%)。15-24 岁年龄组的平均费用最高(1553 欧元)。与皮质类固醇引起的发病率有关的治疗费用估计为 1208 欧元:突尼斯的丘疹性荨麻疹治疗需要根据卫生经济分析进行调整,以降低总体疾病成本和类固醇引起的发病负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tunisie Medicale
Tunisie Medicale Medicine-Medicine (all)
CiteScore
1.00
自引率
0.00%
发文量
72
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信